Chronic consumption of energy drinks and the risk of developing metabolic syndrome in rats
Abstract
The consumption of energy drinks (EDs) has notably increased, particularly among adolescents and young adults, due to their perceived benefits in enhancing physical and cognitive performance. However, growing evidence points to their potential adverse health effects, raising concerns regarding their safety. This study aimed to evaluate and compare the metabolic impacts of three commercially available EDs on male albino rats. A total of 42 rats were randomly assigned into seven groups (n = 6 per group). The control group received a standard basal diet, while the remaining groups administered the three EDs types (Red Bull, Power Horse, and Black) at doses of 10 or 20 mL/kg body weight, twice daily via oral gavage, over a period of eight weeks. At the end of the experiment, body weight gain, adiposity index, and multiple biochemical and physiological parameters were assessed. Serum analyses were performed to evaluate blood glucose levels, metabolic hormones (insulin and leptin), kidney function markers, liver enzymes, lipid profile, cardiovascular risk index, calcium levels, bone mineral density (BMD), and bone mineral concentration (BMC). The findings revealed that energy drink consumption, particularly at the higher dose (20 mL/kg bw) and with the third EDs type, induced significant adverse effects compared to controls. These included elevated blood glucose, leptin, liver enzymes, lipid profile, cardiovascular risk index, and serum calcium, alongside reduced insulin levels,…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.